GLP-1 Vision Loss Lawsuits Against Novo Lilly
Analysis based on 20 articles · First reported Sep 21, 2026 · Last updated Sep 23, 2026
The litigation introduces a new liability overhang for Novo Nordisk and Eli Lilly and Company, threatening the roughly $100bn annual GLP-1 market and potentially weighing on their share prices and investor confidence. Any regulatory action by the United States — Food and Drug Administration to add a NAION warning label could further dampen prescriptions and sales growth across the class.
Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which produces sudden and often permanent vision loss. Plaintiffs claim the companies knew or should have known about an increased NAION risk and failed to adequately warn patients. More than 90 lawsuits have been filed against Novo Nordisk in New Jersey state court since 2025 by patients represented by the personal-injury firm Weitz & Luxenberg, with separate cases in the US District Court for the Eastern District of Pennsylvania. Novo Nordisk calls the claims without merit and says it found no NAION safety signal in its randomized clinical trials, while Eli Lilly and Company says patient safety is its top priority and that it monitors safety reports. The United States — Food and Drug Administration has not added a NAION warning to US labels but is conducting an ongoing review through its Sentinel Initiative. The European_Medicines_Agent estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings, as did the Australia — Therapeutic Goods Administration in Australia. The American Academy of Neurology and the North American Neuro-Ophthalmology Society acknowledge reports of a possible small risk increase but stress the overall risk remains low and the evidence is mixed. The Cleveland Clinic describes NAION as rare but potentially devastating, with no established treatment to reverse the damage.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard